Effects of electronic digital remote management on glucose and lipid metabolism and quality of life in patients with type 2 diabetes

doi:10.3877/cma.j.issn.2095-9605.2022.02.006

Abstract

Abstract:

Objective

To explore the application strategies of electronic digital remote management of patients with type 2 diabetes and its influence on glucose and lipid metabolism and quality of life.

Methods

70 patients diagnosed with type 2 diabetes were selected from January 2020 to January 2021 as the research objects, and divide them into research group and control group by random number method, with 35 cases in each group. The research group adopts electronic digital remote management. The blood glucose levels, C-peptide, and glycosylated hemoglobin (HbA1c), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG) and total cholesterol (TC) levels were compared between the two groups at the time of diagnosis and after 3 months of follow-up , to compare the quality of life ADL score and diabetes self-management 2-SCS score of the two groups of patients.

Results

After 3 months, FPG, 2hPG, HbA1c, TC, TG, and LDL-C levels of the study group were significantly lower than those of the control group (P<0.05), and the fasting, 2 h postprandial average C-peptide and HDL-C levels were significantly higher than those of the control group (P<0.05); There was no statistical difference in the overall average quality of life ADL scores of the two groups before intervention. The ADL scores of the study group who used electronic digital remote management after 3 months were significantly higher than those of the control group (P<0.05); And the 2-SCS scores of the study group were significantly higher than those of the control group (P<0.05).

Conclusions

Electronic digital remote management application strategy can effectively improve the control effect of blood glucose and blood lipids in patients with type 2 diabetes, and improve the patient's quality of life and diabetes self-management ability.

Key words: Electronic digital remote management, Type 2 diabetes, Blood glucose, Blood lipids, Diabetes management.

Feifei Lai, Shu Li, Weiqiong Wu, Yu Li, Huifang Li, Xiaona Zhang. Effects of electronic digital remote management on glucose and lipid metabolism and quality of life in patients with type 2 diabetes[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2022, 08(02): 104-108.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2022.02.006

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2022/V08/I02/104

Figures/Tables 3

References 13

[1]	Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Res Clin Pract, 2018, 138: 271-281
[2]	田浩明，李舍予. 长期血糖控制与糖尿病慢性血管并发症:循证治疗三十年 [J]. 中华糖尿病杂志, 2016, 8(11): 641-644.
[3]	周梅清.电子化远程管理对新诊断2型糖尿病患者综合达标率的影响及成本效益分析 [D]. 南昌大学, 2020.
[4]	中国研究型医院学会糖尿病学专业委员会分级诊疗与基层管理糖尿病学组. 2型糖尿病分级诊疗与质量管理专家共识 [J]. 中国医学前沿杂志(电子版), 2020, 5(12): 38-53.
[5]	贾丽军，谭枫，石文惠, 等. 移动医疗APP在糖尿病防治领域的应用现状 [J].中国慢性病预防与控制, 2017, 25(9): 717-720.
[6]	陈伟菊，张诗毅. 糖尿病远程管理模式的国内外进展 [J/CD]. 中华肥胖与代谢病电子杂志, 2016, 2(4): 205-208.
[7]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版) [J]. 中华糖尿病杂志, 2018, 10(1): 4-67.
[8]	Hu Y, Wen X, Wang F, et al. Effect of telemedicine intervention on hypoglycaemia in diabetes patients: A systematic review and meta -analysis of randomised controlled trials [J]. J Telemed Telecare, 2019, 25(7): 402-413.
[9]	李英夫，熊巨洋. 糖尿病远程医学管理应用的研究热点与趋势 [J]. 中华医学图书情报杂志, 2020, 29(12): 30-35.
[10]	Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013 [J]. JAMA, 2017, 317(24): 2515-2523.
[11]	张红，邓玉凤，孙琳, 等. 远程医疗模式在老年2型糖尿病患者中的临床应用 [J]. 中国老年学杂志, 2017, 37 (12): 2950-2952.
[12]	王菲菲，倪林，胡玉丽, 等. 远程血糖管理对2型糖尿病患者血糖控制及达标率的影响 [J]. 中国现代医生, 2021, 59(01): 5-8.
[13]	高洪伟，武曦蔼，谢玲玎, 等. 中国糖尿病远程管理专家共识(2020版) [J].中日友好医院学报, 2020, 34(06): 323-332 + 320.

组别	例数	性别（男/女）	BMI（kg/m²）	年龄（岁）	合并高血压（%）
研究组	35	17/18	23.4±1.7	44.6±3.7	6（17.1）
对照组	35	19/16	23.5±1.4	45.3±4.1	8（22.9）
t/χ²值		0.229	0.269	0.750	0.357
P值		0.811	0.789	0.456	0.766

组别	例数	性别（男/女）	BMI（kg/m²）	年龄（岁）	合并高血压（%）
研究组	35	17/18	23.4±1.7	44.6±3.7	6（17.1）
对照组	35	19/16	23.5±1.4	45.3±4.1	8（22.9）
t/χ²值		0.229	0.269	0.750	0.357
P值		0.811	0.789	0.456	0.766

组别	例数	血糖（mmol/L）		C肽（ng/mL）		HbA1c （%）	TC （mmol/L）	TG （mmol/L）	LDL-C （mmol/L）	HDL-C （mmol/L）
组别	例数	FPG	2hPG	空腹C肽	餐后2 h C肽	HbA1c （%）	TC （mmol/L）	TG （mmol/L）	LDL-C （mmol/L）	HDL-C （mmol/L）
研究组	35
干预前		8.43±0.61	13.64±1.76	1.79±0.53	3.22±0.61	7.52±0.42	5.13±0.47	3.45±0.41	3.43±0.41	0.89±0.15
3月后		6.24±0.43^*	8.04±0.62^*	2.69±0.48*^#	4.52±0.43^*#	6.31±0.34^*#	4.42±0.60^*#	2.41±0.37^*#	2.74±0.33^*#	1.16±0.14^*#
对照组	35
干预前		8.47±0.58	13.72±1.52	1.82±0.51	3.04±0.52	7.60±0.39	5.16±0.55	3.40±0.39	3.47±0.42	0.91±0.15
3月后		7.21±0.82^*	8.83±0.54^*	2.11±0.42	3.72±0.44	6.65±0.33^*	4.68±0.51^*	2.86±0.33^*	3.10±0.31^*	0.99±0.11^*

组别	例数	血糖（mmol/L）		C肽（ng/mL）		HbA1c （%）	TC （mmol/L）	TG （mmol/L）	LDL-C （mmol/L）	HDL-C （mmol/L）
组别	例数	FPG	2hPG	空腹C肽	餐后2 h C肽	HbA1c （%）	TC （mmol/L）	TG （mmol/L）	LDL-C （mmol/L）	HDL-C （mmol/L）
研究组	35
干预前		8.43±0.61	13.64±1.76	1.79±0.53	3.22±0.61	7.52±0.42	5.13±0.47	3.45±0.41	3.43±0.41	0.89±0.15
3月后		6.24±0.43^*	8.04±0.62^*	2.69±0.48*^#	4.52±0.43^*#	6.31±0.34^*#	4.42±0.60^*#	2.41±0.37^*#	2.74±0.33^*#	1.16±0.14^*#
对照组	35
干预前		8.47±0.58	13.72±1.52	1.82±0.51	3.04±0.52	7.60±0.39	5.16±0.55	3.40±0.39	3.47±0.42	0.91±0.15
3月后		7.21±0.82^*	8.83±0.54^*	2.11±0.42	3.72±0.44	6.65±0.33^*	4.68±0.51^*	2.86±0.33^*	3.10±0.31^*	0.99±0.11^*

组别	例数	ADL		2-SCS评分（3月后）
组别	例数	干预前	3月后	总体自我管理	饮食	运动	遵医嘱用药	监测血糖	足部护理	高低血糖处理
研究组	35	83.2±3.1	92.2±3.4	95.3±2.6	17.4±2.8	15.2±1.8	12.3±0.9	14.6±1.3	16.2±1.7	14.6±1.5
对照组	35	82.9±2.8	87.4±3.6	82.4±4.3	15.2±3.3	13.8±1.9	9.6±1.5	12.3±1.4	14.1±1.4	13.4±0.9
t值		0.425	5.735	15.19	4.312	3.165	9.131	7.122	5.641	4.058
P值		0.672	<0.001	<0.001	<0.001	0.002	<0.001	<0.001	<0.001	<0.001

Please choose a citation manager

Content to export